latest news releases from the newsroom
CDMA Development Group
CDMA Industry Witnesses Record-Breaking Growth
COSTA MESA, Calif., Feb. 21, 2007 (PRIME NEWSWIRE) -- The CDMA Development Group (CDG) today announced that there were 100 million new CDMA2000(r) subscriber adds in 2006. Currently, there are more than 325 million CDMA2000 subscribers, including 55 million CDMA2000 1xEV-DO broadband subscribers, representing a 125% increase in EV-DO subscribers from the previous year. Including cdmaOne, there are now more than 370 million CDMA subscribers worldwide. Most of the growth came from the Asia Pacific region, followed by North America, Latin America and the Caribbean, and then Europe, Africa and the Middle East.
Gevity HR, Inc.
Gevity Announces 25th Consecutive Quarterly Dividend
BRADENTON, Fla., Feb. 21, 2007 (PRIME NEWSWIRE) -- Gevity (Nasdaq:GVHR), which serves as the full-service human resources department for small and mid-sized businesses, declared a dividend of $0.09 per share of common stock, payable on April 30, 2007 to shareholders of record on April 16, 2007.
Nord Resources Corporation
Nord Resources Corporation Announces Failure by Platinum Diversified Mining, Inc. to Pay Termination Fee Under Merger Agreement
TUCSON, Ariz., Feb. 21, 2007 (PRIME NEWSWIRE) -- Mr. Ronald Hirsch, Chairman of the Board of Directors of Nord Resources Corporation ("Nord") (Pink Sheets:NRDS) announced today that Platinum Diversified Mining, Inc. ("Platinum") has failed to pay the $2,000,000 termination fee demanded by Nord in connection with the termination of the Merger Agreement respecting the proposed acquisition of Nord by Platinum (the "Merger"). In its Notice of Termination dated February 15, 2007, Nord demanded payment of the termination fee no later than the close of business on Tuesday, February 20, 2007, and placed Platinum on notice that it has reserved all of its rights to pursue Platinum for damages.
MediciNova to Present Phase II Clinical Trial Results for MN-001, a Novel Oral Treatment for Bronchial Asthma, at the 2007 AAAAI Annual Meeting
SAN DIEGO, Feb. 21, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc. (Nasdaq:MNOV) (Hercules Market of the Osaka Securities Exchange: Code Number: 4875), a biopharmaceutical company focused on accelerating the global development and commercialization of innovative pharmaceutical products, today announced that one of its clinical investigators will present data from a Phase II clinical study of MN-001, MediciNova's investigational oral treatment for bronchial asthma. As previously announced, MN-001 was well tolerated and significantly improved measures of respiratory function in asthma patients compared to placebo in this trial.